Diclofenac - Iroko Pharmaceuticals

Drug Profile

Diclofenac - Iroko Pharmaceuticals

Alternative Names: Diclofenac nano-formulation - Iroko Pharmaceuticals; Diclofenac Test; IP 880; lower dose submicron diclofenac - Iroko; Zorvolex

Latest Information Update: 08 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator iCeutica
  • Developer Algorithm; Iroko Pharmaceuticals
  • Class Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Acute pain; Musculoskeletal pain; Postoperative pain
  • No development reported Dental pain

Most Recent Events

  • 31 Oct 2018 Egalet enters into a purchase agreement with Iroko Pharmaceuticals to acquire diclofenac
  • 22 Oct 2018 No development reported - Phase-II for Postoperative pain (In adolescents, In children) in USA (PO)
  • 07 Dec 2016 Iroko files a Paragraph IV law suit against Lupin alleging the infringement of Iroko's patents protecting the Zorvolex® products
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top